Skip to main content
. 2023 Feb 23;12(2):266–276. doi: 10.21037/tlcr-22-556

Figure 2.

Figure 2

Progression-free survival (A) and overall survival (B) of patients with advanced non-squamous NSCLC treated with the association of pembrolizumab plus chemotherapy, according to the intensity of programmed cell-death-1-ligand-1 expression. NSCLC, non-small cell lung cancer.